Robert J. Chaponis, PharmD, RPh
Board Chairman
Principal Consultant
Pointe North Consulting, LLC
Dr. Robert Chaponis is the owner of Pointe North Consulting, LLC, a company focused on providing clinical development and medical affairs advisory and operational services to the pharmaceutical, healthcare, CRO, and life sciences industries. As a senior level R&D leader, Dr. Chaponis has a strong track record of fostering innovation and bringing novel medicinal products to the market across several diverse therapeutic areas. His 35+ years of experience in the pharma industry leading medical affairs and clinical development teams have encompassed both prescription (Rx) and over-the counter (OTC) drug development (Phases 1-4), medical marketing initiatives, global and regional team leadership, public health advocacy, and the application of outcomes research methodology to evaluate the value, quality of life, and real-world effectiveness of medicines. Most recently, Dr. Chaponis completed 14 years of combined service at GlaxoSmithKline (GSK) Consumer Healthcare and Novartis Consumer Healthcare, which consolidated its business operations into GSK in 2015 through a joint venture. Robert has also held a variety of medical and clinical leadership positions on the Rx side of Pfizer Pharmaceuticals, Pharmacia Corporation, and Schering-Plough Corporation. In addition, he has worked on the consultant side of geriatric medicine bringing new innovations to the conduct of research, disease management, medical information, and continuing medical education. Dr. Chaponis holds a Doctor of Pharmacy (PharmD) degree from Shenandoah University and a B.S. degree of Pharmacy from Temple University.
Matthew Bardin, PharmD, BCPS
Romark, L.C.
Dr. Matthew Bardin is an experienced medical affairs and clinical operations professional with over 18 years of experience in the pharmaceutical industry. Unique to his strong background in medical affairs, clinical operations, and pharmacovigilance, he has a firm understanding of the needs and objectives of each team and often served in a cross-functional capacity between the roles as they are naturally intertwined. He has held several positions at Romark, L.C., where he currently serves as the Vice President of Medical Affairs; previous positions include Medical Science Liaison, Director of Clinical Research, and Vice President of Clinical Research. His time in the industry has garnered experience in medical information, clinical monitoring, pharmacovigilance, good clinical practice (GCP), biotechnology, pharmacy, and drug development. In addition to Mr. Bardin’s professional experience, he is a Board-Certified Pharmacotherapy Specialist and has a Doctor of Pharmacy degree from the McWhorter School of Pharmacy at Samford University (Magna Cum Laude), as well as a Bachelor of Science in Biochemistry from Florida State University.
Jay Horrow, MD, MS, FAHA, FACC
Bristol Myers Squibb
Dr. Jay Horrow currently serves as the Clinical Lead for Factor XI Outcome Trials at Bristol Myers Squibb, where he also recently served as the Clinical Development Lead for cardiovascular global development. He began a career in pharmaceutical medicine as Vice President for Clinical Development at IBEX Technologies, and then later joined AstraZeneca as Director in Clinical Development and study physician for the SPORTIF V trial for Exanta®. He has also held positions as Medical Science Director for multiple products at AstraZeneca. His career has also included work in academic medicine, as he served 3 years as Chairman of the Anesthesiology Department at Drexel University College of Medicine. Throughout his pharmaceutical medicine career, he has continued to provide clinical anesthesia care to patients and to teach anesthesia and clinical trial design to medical students and residents, and biostatistics in the pharmaceutical industry. Dr. Horrow holds a degree in Electrical Engineering from Princeton University and Applied Statistics from Villanova University. He received his MD from the University of Pennsylvania; following postgraduate training, he served as Instructor in Anesthesia at Harvard Medical School, then Assistant Professor of Anesthesiology at Hahnemann University. Dr. Horrow has published over 100 articles in peer-reviewed journals, including the New England Journal of Medicine, Lancet, JAMA, JACC, Circulation, Radiology, Anesthesia & Analgesia, and Anesthesiology, as well as 37 book chapters.
Gil Price, MD
President & CEO, Retired NeuroBo Pharmaceuticals
Dr. Gil Price is a clinical trial Medical Monitor and Pharmacovigilance expert. He has years of experience as the head of Safety Management Teams (SMTs), multiple Data Safety Monitoring Boards, as well as, protocol development and safety support from FIH to Phase IV clinical trials. While his therapeutic horizon is broad, it has been dominated by oncology, infectious disease, and rare disease. Dr. Price was previously responsible for the strategic and tactical management of all business at Drug Safety Solutions. After a successful 20-year history, Drug Safety Solutions was acquired in June 2017 by Linden CapitalPartners. From 2017 to 2019, Dr. Price functioned as the Chief Medical Officer for the global ProPharma Group, a Linden subsidiary. His most recent role was the President and CEO of NeuroBo Pharmaceuticals in Boston, MA, from where he retired in 2023. Over the years Dr. Price has served on corporate boards, including public, private, and not-for-profit. His board duties included the Chairman’s role on Compensation and Governance as well as a member’s role on Audit. Dr. Price received his undergraduate degree from the University of Rio Grande and completed his Doctor of Medicine degree from the University of Santiago. He completed his residency with the Department of Internal Medicine at the Aultman Hospital/Northeastern Ohio University College of Medicine, after which he began his industry career at Glaxo, Inc. as the Director of Medical Affairs.